Avibactam, a non-␤-lactam ␤-lactamase inhibitor with activity against extended-spectrum ␤-lactamases (ESBLs), KPC, AmpC, and some OXA enzymes, extends the antibacterial activity of ceftazidime against most ceftazidime-resistant organisms producing these enzymes. In this study, the bactericidal activity of ceftazidime-avibactam against 18 Pseudomonas aeruginosa isolates and 15 Enterobacteriaceae isolates, including wild-type isolates and ESBL, KPC, and/or AmpC producers, was evaluated. Ceftazidime-avibactam MICs (0.016 to 32 g/ml) were lower than those for ceftazidime alone (0.06 to >256 g/ml) against all isolates except for 2 P. aeruginosa isolates (1 bla VIM -positive isolate and 1 bla OXA-23 -positive isolate). The minimum bactericidal concentration/MIC ratios of ceftazidime-avibactam were <4 for all isolates, indicating bactericidal activity. Human serum and human serum albumin had a minimal effect on ceftazidime-avibactam MICs. Ceftazidime-avibactam time-kill kinetics were evaluated at low MIC multiples and showed time-dependent reductions in the number of CFU/ml from 0 to 6 h for all strains tested. A >3-log 10 decrease in the number of CFU/ml was observed at 6 h for all Enterobacteriaceae, and a 2-log 10 reduction in the number of CFU/ml was observed at 6 h for 3 of the 6 P. aeruginosa isolates. Regrowth was noted at 24 h for some of the isolates tested in time-kill assays. These data demonstrate the potent bactericidal activity of ceftazidime-avibactam and support the continued clinical development of ceftazidime-avibactam as a new treatment option for infections caused by Enterobacteriaceae and P. aeruginosa, including isolates resistant to ceftazidime by mechanisms dependent on avibactam-sensitive ␤-lactamases.
T
he CDC estimates that each year in the United States 26,000 health care-associated infections are caused by extended-spectrum ␤-lactamase (ESBL)-producing Enterobacteriaceae strains and 6,700 infections are caused by multidrug-resistant Pseudomonas aeruginosa strains (1) . These bacteria are resistant to commonly used cephalosporins. One strategy to overcome this resistance is to combine a cephalosporin with a ␤-lactamase inhibitor. The currently available ␤-lactamase inhibitors, clavulanic acid, sulbactam, and tazobactam, are effective against certain enzymes of the Ambler class A ␤-lactamases (TEM and SHV) but are ineffective against Ambler class C enzymes (AmpC) and class A carbapenemases (KPC) (2) . Avibactam is a novel non-␤-lactam ␤-lactamase inhibitor with inhibitory activity against class C enzymes, most class A enzymes (including KPCs), and some class D (OXA) carbapenemases, but like other ␤-lactamase inhibitors, it does not inhibit class B enzymes (metallo-␤-lactamases) (3) . Ceftazidime is an expanded-spectrum cephalosporin with broadspectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa. When ceftazidime is combined with avibactam, the spectrum of activity is expanded to include organisms producing these ␤-lactamases (4) (5) (6) . Furthermore, in a large United States-focused surveillance program conducted in 2012, ceftazidime-avibactam had antimicrobial activity against 99.8% of Enterobacteriaceae isolates, including those with an ESBL phenotype, and 96.9% of P. aeruginosa isolates (6) . The present study details the bactericidal activity of ceftazidime-avibactam against a panel of P. aeruginosa and Enterobacteriaceae clinical and reference isolates. Isolates were tested in broth microdilution assays in order to determine the MIC and the minimum bactericidal concentration (MBC). The effects of human serum and human serum albumin on the ceftazidime-avibactam MICs of these isolates were also determined. Finally, the bactericidal activity of ceftazidimeavibactam against a subset of P. aeruginosa and Enterobacteriaceae isolates was studied in time-kill assays.
(Preliminary results from this study were presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, CO, 10 to 13 September 2013 [7] .)
MATERIALS AND METHODS
Isolates and reagents. Eighteen P. aeruginosa and 15 Enterobacteriaceae isolates, including wild-type and ␤-lactamase-positive isolates, were used in this study. The isolates and their bla genes are listed in Table 1 . Isolates were obtained from the American Type Culture Collection (ATCC; Manassas, VA), JMI Laboratories (North Liberty, IA), or the culture collection of Cerexa, Inc. ␤-Lactamase gene information was provided by the isolate source or was determined by use of a Check-Points Health BV (Wageningen, The Netherlands) microarray. Whole-genome DNA was isolated from the bacteria by column filter centrifugation using a MoBio UltraClean microbial DNA isolation kit (catalog no. 12224-250). The Check-Points Health BV Check-MDR CT101 or CT103 kit was used for the molecular detection and identification of the carbapenemase, AmpC, and ESBL genes (8, 9) .
Ceftazidime pentahydrate (catalog no. 1098130, lot no. I0I233 and I1K237; USP), meropenem (catalog no. 1392454, lot no. 10J244; USP), ceftriaxone (catalog no. C5793, lot no. 060M0750; Sigma), avibactam (lot no. L0003145; Forest Laboratories, Inc.), tazobactam (catalog no. 1643383, lot no. G0I210; USP), colistin (catalog no. C4461, lot no. 081M1525V; Sigma), and piperacillin sodium (catalog no. P8396, lot no. 060M0766 and SLBG2546V; Sigma) were prepared in solvents according to CLSI guidelines (10, 11) . Human serum was purchased from Sigma (catalog no. H4522, lot no. SLBB2992V) and was heat inactivated at 55°C for 30 min and then filtered through a 0.22-m-pore-size filter. Human serum albumin was also purchased from Sigma (catalog no. A9511, lot no. 091M7004V) and was dissolved in cation-adjusted Mueller-Hinton broth (CAMHB) to a concentration of 80 mg/ml (8%). MIC and MBC determinations. MIC and MBC determinations were performed according to CLSI guidelines (CLSI documents M07-A9, M100-S22, M100-S23, and M26-A) (10) (11) (12) (13) . Briefly, antibiotic test plates were prepared in a 2-fold dilution series containing 10 l 10ϫ the desired final concentration in 96-well round-bottom microtiter plates. Bacterial cell suspensions were prepared at an equivalent to a 0.5 McFarland standard. Bacterial suspensions were diluted in CAMHB so that the final culture density in the microtiter plates was equal to 5 ϫ 10 5 CFU/ml. Cultures were plated on agar to verify the initial inoculum density for MBC testing. Bacteria (90 l) were then added to the microtiter plates containing antibiotic and incubated for 18 h at 35 Ϯ 2°C. After the MIC was recorded as the lowest concentration where there was no visible bacterial growth, MBC assays was performed by plating the contents of the wells (approximately 100 l) in which there was no visible growth onto Mueller-Hinton agar (MHA). The MBC was recorded as the concentration of drug that resulted in a Ն3-log 10 decrease in the number of CFU/ml after 18 to 24 h of incubation. For assays with 50% human serum, antibiotics were diluted in 2ϫ CAMHB. For ␤-lactam-␤-lactamase inhibitor combinations, the inhibitors avibactam and tazobactam were tested at a fixed concentration of 4 g/ml. For assays testing the effect of serum on the MIC, bacterial suspensions were diluted in CAMHB containing 8% human serum albumin or in 100% human serum so that the final concentration of human serum albumin was 4% or the final concentration of human serum was 50%. Quality control was monitored with Escherichia coli strains ATCC 25922 and ATCC 35128, P. aeruginosa strain ATCC 27853, and Klebsiella pneumoniae strain ATCC 700603.
Time-kill studies. Time-kill studies were performed according to previously published methods, including those described by CLSI document M26-A (13). Briefly, freshly prepared colonies were resuspended in 10 ml CAMHB and incubated in a shaking water bath (37°C, 180 rpm) for 1 to 2 h. Cultures were then diluted to a 0.5 McFarland standard (approximately 10 8 CFU/ml) and further diluted 1:20 in CAMHB so that the starting inoculum was approximately 5 ϫ 10 6 CFU/ml. Ceftazidime was added to the prepared bacterial suspensions so that the final ceftazidime concentration was 2ϫ, 4ϫ or 8ϫ the MIC of ceftazidime-avibactam, and avibactam was added to a final concentration of 4 g/ml. Ceftazidime alone, colistin, and meropenem were diluted in the prepared bacterial suspensions at 8ϫ the MIC only. A growth control with no antibiotic was also included. The starting inoculum was determined from the growth control tube immediately after dilution and was recorded as the count at time zero. After addition of antibiotics, the starting inoculum was 1 ϫ 10 6 to 5 ϫ 10 6 CFU/ml. Tubes were incubated in a shaking water bath (37°C, 180 rpm), and viability counts were performed at 1, 2, 4, 6, and 24 h by removing 200 l of the culture, diluting as appropriate, and plating 100 l on MHA. MHA plates were incubated at 37°C for at least 18 h. Colonies were counted, and the results were recorded as the number of CFU/ml. A Ն3-log 10 decrease in the number of CFU/ml was considered bactericidal.
Variations on time-kill studies. Three variations on the time-kill method described above were also employed to additionally probe the characteristics of ceftazidime-avibactam kill kinetics at different ␤-lactamase inhibitor concentrations. Each of these experiments used the methods described above with the exceptions noted below. In the first experiment, an additional 4 g/ml of ␤-lactamase inhibitor (avibactam or tazobactam, as appropriate) was added to the culture at the 6-h time point to determine if regrowth could be potentially attributed to inhibitor degradation. Samples were then taken at the 24-h time point. A second experiment monitored the effects of various inhibitor concentrations by evaluating the rate of kill of 4ϫ MIC antibiotic (as measured in the presence of 4 g/ml inhibitor) in combination with 2, 4, 6, 8, 10, or 12 g/ml avibactam or tazobactam. In a third set of experiments, a comparison of the activities of avibactam and tazobactam was made by testing ceftazidime-avibactam, ceftazidime-tazobactam, and ceftazidime at 2ϫ, 4ϫ, and 8ϫ the ceftazidime-avibactam MIC so that all antibiotic-inhibitor combinations were tested at the same concentration.
RESULTS
MIC and MBC studies. The addition of avibactam to ceftazidime extended the antimicrobial and bactericidal activity of ceftazidime for most of the bla gene-positive ceftazidime-and meropenemresistant isolates tested ( Table 1 ). The exceptions were 2 P. aeruginosa isolates (CML1458 and CML1455) with ceftazidime MICs of 16 and 32 g/ml against which the activity of ceftazidime remained unchanged by the addition of avibactam at 4 g/ml. Isolate CML1455 was positive for the gene bla VIM , and isolate CML1458 was positive for bla .
According to CLSI interpretative criteria, 22.2% of P. aeruginosa isolates were susceptible to ceftazidime (MIC Յ 8 g/ml), 16.7% of P. aeruginosa isolates were susceptible to meropenem (MIC Յ 2 g/ml), 27.8% of P. aeruginosa isolates were susceptible to piperacillin-tazobactam (MIC Յ 16/4 g/ml), and 100% of P. aeruginosa isolates were susceptible to colistin (MIC Յ 2 g/ml) (there are no CLSI interpretive criteria for ceftriaxone and P. aeruginosa) (11) . Among the Enterobacteriaceae isolates, 33.3% were susceptible to ceftazidime (MIC Յ 4 g/ml), 22.2% were susceptible to ceftriaxone (MIC Յ 1 g/ml), 66.7% were susceptible to meropenem (MIC Յ 1 g/ml), and 44.4% were susceptible to piperacillin-tazobactam (MIC Յ 16/4 g/ml) (there are no CLSI interpretive criteria for colistin and Enterobacteriaceae) (11) . There are currently no approved CLSI interpretive criteria for ceftazidime-avibactam. The ceftazidime-avibactam MIC 50 and MIC 90 values for P. aeruginosa isolates were 4 and 16 g/ml, respectively, which were lower than those of the other antibiotics tested except those of colistin, for which the MIC 50 and MIC 90 values were 0.5 and 0.5 g/ml, respectively (Table 2) . For Enterobacteriaceae isolates, ceftazidime-avibactam MIC 50 and MIC 90 values were 0.25 and 1 g/ ml, respectively, which were lower than those of the other antibiotics tested except those of colistin (MIC 50 and MIC 90 values, 0.06 and 0.25 g/ml, respectively) and the MIC 50 (but not MIC 90 ) of meropenem (MIC 50 and MIC 90 values, 0.06 and 32 g/ml, respectively).
The MBCs for all the drugs tested, including ceftazidimeavibactam, were typically within 1 to 2 dilutions of the MIC. The one exception for ceftazidime-avibactam was with Serratia marcescens ATCC 14756, against which the MBC/MIC ratio was 4 (Table 1). Similar results were also observed for ceftobiprole in a study by Deshpande et al., where the MBC/MIC ratios measured against certain S. marcescens strains were Ͼ4 (14) . Ceftazidime-avibactam MBC/MIC ratios were Յ2 against all other isolates tested, indicating the bactericidal activity of this combination.
Effect of serum on MICs and MBCs. The MIC values of ceftazidime and ceftazidime-avibactam in the presence of 50% human serum or 4% human serum albumin remained within 1 to 2 dilutions of the MIC in their absence, indicating that there was no significant effect of serum on ceftazidime or ceftazidime-avibactam MICs (Table 1) . A significant shift in MICs under the same conditions was observed for ceftriaxone, which is known to have a high level of binding to human serum (85 to 95%) (15) . Ceftriaxone MIC values increased by 4 or more dilutions for nine of the isolates tested in the presence of albumin (data not shown), with an average fold increase in MIC of 5.5 Ϯ 3 for P. aeruginosa and 21.4 Ϯ 10.67 for Enterobacteriaceae ( Table 2 ). The effect of 4% albumin on ceftriaxone MICs appeared to be greater than the effect of 50% serum, as can be seen by the average fold increase values for Enterobacteriaceae in Table 2 . This may be due to the fact that 50% serum contains 2% albumin, so 4% albumin contains more of the serum protein most often responsible for binding cephalosporins. It is worth noting that for 18 of the 33 isolates tested, the ceftriaxone MIC was at or greater than the highest concentration tested, so no serum effect could be assessed with these strains. Piperacillin-tazobactam MICs were elevated by 4 dilutions or more in the presence of 4% albumin when testing 5 Enterobacteriaceae isolates (CML138, CML2255, CML2341, CML148, and CML2280), although this was not seen in 50% human serum (individual isolate data not shown). Serum and albumin had little to no effect on meropenem and colistin MICs (Table 2) .
Time-kill studies. Time-kill studies for ceftazidime-avibactam, ceftazidime, meropenem, and colistin were performed on 6 P. aeruginosa and 8 Enterobacteriaceae isolates (indicated in Table  1 ). Ceftazidime-avibactam caused decreases in the number of CFU/ml over the 0-to 6-h time period against all strains at all multiples of the MIC tested (Table 3 ). All Enterobacteriaceae isolates had at least a 3-log 10 decrease in the number of CFU/ml with treatment with ceftazidime-avibactam at 4ϫ and 8ϫ MICs at 6 h. All P. aeruginosa isolates had at least a 1-log 10 decrease in the number of CFU/ml with treatment with ceftazidime-avibactam at 8ϫ MIC at 6 h. However, various degrees of regrowth were seen for isolates at the 24-h time point (Table 3) .
Ceftazidime-avibactam was bactericidal at 24 h when tested at 8ϫ MIC against two of three strains of E. coli (the CML1468 bla KPC -positive isolate and the CML2255 isolate positive for the bla CTX-M-15 , bla TEM-1 , and bla OXA-1 genes), while a 2.5-log 10 decrease in the number of CFU/ml was observed for E. coli ATCC 25922 (individual isolate data not shown). A similar phenomenon for ATCC 25922 was observed at 6 h for 8ϫ MIC of colistin and a MICs that were Ͼ256 g/ml or Ͼ128 g/ml were not included in calculations of the fold change in MIC.
meropenem. Colistin at 8ϫ MIC was not bactericidal against either E. coli isolate CML1468 or E. coli isolate CML2255 at 24 h. Ceftazidime-avibactam was less bactericidal against the four Klebsiella pneumoniae isolates (CML128, CML138, CML148, and CML2280) and one Klebsiella oxytoca isolate (CML2251) tested in this study than it was against the E. coli isolates (individual isolate data not shown). At the 6-h time point, all concentrations of ceftazidime-avibactam caused a Ͼ3-log 10 decrease in the number of CFU/ml of these strains except 2ϫ MIC of ceftazidime-avibactam against bla TEM-129 -positive K. oxytoca CML2251. However, a 3-log 10 reduction in the number of CFU/ml at 24 h by 8ϫ MIC of ceftazidime-avibactam was observed for only one Klebsiella isolate (bla KPC-2 -, bla SHV-27 -, and bla TEM-1 -positive isolate K. pneumoniae CML128). None of the comparator agents tested was bactericidal at 8ϫ MIC at 24 h against any of the strains tested (except for meropenem against bla KPC-2 -, bla SHV-27 -, and bla TEM-1 -positive isolate K. pneumoniae CML128).
Ceftazidime-avibactam at 8ϫ MIC caused at least a 1-log 10 reduction in the number of CFU/ml at 6 h for all the P. aeruginosa isolates tested (Table 3) . Ceftazidime-avibactam at 2ϫ and 4ϫ MIC was bactericidal (Ͼ3-log 10 -CFU/ml decrease) against wildtype P. aeruginosa ATCC 27853 at 6 h (individual isolate data not shown). The decrease in the number of CFU/ml at 6 h for the other P. aeruginosa isolates tested ranged from 0.57 to 2.71 log 10 at 4ϫ MIC and 1.09 to 2.68 log 10 at 8ϫ MIC. Ceftazidime-avibactam was not observed to have bactericidal activity at 24 h against any P. aeruginosa isolate, with no more than a 1-log 10 decrease in the number of CFU/ml occurring at any concentration of ceftazidime-avibactam tested (Table 3 ). In addition, none of the comparator agents were bactericidal against this strain set at 24 h when tested at 8ϫ MIC, highlighting the difficulty in achieving a bactericidal response at 24 h against P. aeruginosa in time-kill experiments.
Effect of ␤-lactamase inhibitor and inhibitor concentration on time-kill studies.
Additional time-kill studies were performed to better understand the regrowth observed in the initial time-kill studies. Four isolates were chosen for these studies, including a bla CTX-M-15 -, bla TEM-1 -, and bla OXA-1 -positive E. coli isolate (isolate CML2255), a bla KPC-2 -, bla SHV-27 -, and bla TEM-1 -positive K. pneumoniae isolate (isolate CML128), P. aeruginosa isolate CML1039, and bla TEM-24 -positive P. aeruginosa isolate CML1040. In order to assess whether regrowth in time-kill studies might be unique to avibactam or common to ␤-lactamase inhibitors, timekill studies were conducted with piperacillin-tazobactam, ceftazidime-tazobactam, and ceftazidime-avibactam. Additionally, to test whether the ␤-lactamase inhibitor might not have been present in sufficient excess of the amount of ␤-lactamase enzymes during regrowth from 6 to 24 h to fully inhibit the enzymes, additional ␤-lactamase inhibitor was added at 6 h.
Regrowth was observed at 24 h for all 3 drug combinations tested, and we found that the effect of adding additional ␤-lactamase inhibitor was dependent on the antibiotic-inhibitor combination and on the isolate tested (Fig. 1) . For P. aeruginosa isolate CML1039, addition of 4 g/ml tazobactam at 6 h caused a less than 0.3-log 10 decrease in the number of CFU/ml compared to the effect of addition of no additional inhibitor in both the piperacillin-tazobactam and ceftazidime-tazobactam combinations (data not shown). For the ceftazidime-avibactam combination against isolate CML1039, the addition of an extra 4 g/ml avibactam to the 4ϫ MIC treatment caused a 1.02-log 10 decrease in the number of CFU/ml compared to the decrease achieved without the addition of additional avibactam (data not shown). Addition of avibactam at 6 h to 8ϫ ceftazidime-avibactam MIC caused a 1.34-log 10 decrease in the number of CFU/ml for bla TEM-24 -positive P. aeruginosa isolate CML1040 (Fig. 1A) . The addition of tazobactam at 6 h to 8ϫ ceftazidime-tazobactam MIC and 8ϫ piperacillin-tazobactam MIC led to a greater than 1.8-log 10 decrease in the number of CFU/ml at 24 h (Fig. 1B and C) . Addition of 4 g/ml avibactam at 6 h to ceftazidime-avibactam caused a decrease in bacterial counts for bla KPC-2 -, bla SHV-27 -, and bla TEM-1 -positive K. pneumoniae isolate CML128 at 24 h for all concentrations of ceftazidime tested; avibactam added to the 2ϫ ceftazidime-avibactam MIC suspension caused a 1.26-log 10 decrease in the number of CFU/ml, avibactam added to the 4ϫ ceftazidime-avibactam MIC suspension caused a 5.48-log 10 decrease in the number of CFU/ml, and avibactam added to the 8ϫ ceftazidime-avibactam MIC suspension caused a 2.92-log 10 decrease in the number of CFU/ml (data not shown). Addition of 4 g/ml tazobactam at 6 h to ceftazidime-tazobactam cultures of this isolate caused a 0.76-log 10 decrease in the number of CFU/ml, and addition of 4 g/ml tazobactam to the piperacillin-tazobactam cultures had no effect on the time-kill curve for this isolate (data not shown). The addition of avibactam at 6 h to cultures of E. coli isolate CML2255 with 8ϫ ceftazidime-avibactam MIC caused a 1.81-log 10 decrease in the number of CFU/ml compared to that in cultures with no additional inhibitor (Fig. 1D) . The addition of tazobactam at 6 h caused the greatest effect for this isolate when added to 2ϫ ceftazidime-tazobactam MIC and when added to 4ϫ piperacillin-tazobactam MIC, causing 0.65-log 10 and 1.16-log 10 decreases in the numbers of CFU/ml, respectively (Fig. 1D) .
In separate experiments, the effect of the amount of avibactam present in the cultures on the ceftazidime-avibactam time-kill kinetics of the isolates was determined. Avibactam was tested at a The isolates used in the time-kill studies are indicated in Table 1 . b A negative sign indicates a decrease in the log 10 number of CFU/ml from the starting inoculum.
different concentrations (2, 4, 6, 8, 10, and 12 g/ml) in combination with ceftazidime at 4ϫ the ceftazidime-avibactam MIC of the isolate tested, as determined with avibactam at 4 g/ml. Overall, the most significant difference in the time-kill curves was seen with 2 g/ml avibactam, where typically, less killing and more regrowth at 24 h were observed (data not shown). All the other concentrations of avibactam tested had similar time-kill curves, with the exception of the curve for one K. pneumoniae isolate, isolate CML128, where avibactam concentrations of Ն8 g/ml in combination with ceftazidime were bactericidal, whereas regrowth occurred with avibactam concentrations that were Յ6 g/ml (data not shown). In order to compare the relative in vitro activities of the agents on a per weight basis, a third set of time-kill experiments was performed, in which the same concentration of ceftazidime was used for each of 3 conditions: ceftazidime-avibactam, ceftazidime-tazobactam, and ceftazidime alone. The ceftazidime concentrations were 2ϫ, 4ϫ, and 8ϫ the MIC of ceftazidime-avibactam for the isolate. Avibactam and tazobactam were both tested at 4 g/ml. Ceftazidime and ceftazidime-tazobactam did not inhibit the growth of any isolate at the concentrations tested, except for 0.33-to 1.29-log 10 killing by ceftazidime-tazobactam of E. coli CML2255 at the 6-h time point (Table 4 ). The curves for isolates treated with ceftazidime alone and ceftazidime-tazobactam were almost identical to those for the untreated isolates, whereas those for isolates treated with ceftazidime-avibactam showed killing from 0 to 6 h.
DISCUSSION
The data in this study highlight the effect of avibactam on ceftazidime MICs against Enterobacteriaceae and P. aeruginosa isolates with ␤-lactamase genes. Ceftazidime MICs against 17 of 20 ␤-lactamase-expressing isolates were lowered by 4-to 512-fold with the addition of 4 g/ml avibactam. The only exceptions were strain ATCC 35218, for which the ceftazidime and ceftazidime-avibactam MICs were the same, a metallo-␤-lactamase-positive bla VIM -producing P. aeruginosa isolate, and a bla OXA-23 -positive P. aeruginosa isolate, which produce enzymes against which avibactam is known to have little to no effect. VIM-type enzymes are class B metallo-␤-lactamases, and avibactam is not expected to have an effect on enzymes from this class. OXA-23 is a member of the carbapenem-hydrolyzing class D ␤-lactamases, none of which significantly hydrolyzes expanded-spectrum cephalosporins, including ceftazidime (16, 17) . The mechanism of ceftazidime-avibactam resistance of that isolate is thus unexplained and is unlikely to be ␤-lactamase mediated. In general, ceftazidime-avibactam MIC values were most comparable to those of colistin. The MBC/MIC ratio was Յ2 against the majority (97%) of isolates tested (the MBC/MIC ratio was 4 against the one S. marcescens isolate tested). On the basis of the MBC/MIC ratios of Յ4 obtained with this isolate set, ceftazidime-avibactam can be considered a bactericidal drug combination. These results also show that there was no significant effect of human serum or human serum albumin on ceftazidime-avibactam MICs. This is to be expected for ceftazidime, since it has little serum binding activity (18) . The MBC/MIC ratios obtained for all antibiotics are in general agreement with the known protein binding characteristics of these agents (from the product labels, the levels of plasma protein binding are Յ10% for ceftazidime, 85 to 95% for ceftriaxone, ϳ30% for piperacillin and tazobactam, ϳ2% for meropenem, and Ͻ10% for avibactam) (15, (19) (20) (21) ; AstraZeneca and Forest Laboratories, Inc., unpublished information). For colistin, the measurement of percent protein binding is complex, involves multiple plasma proteins, and is dose dependent; therefore, a consistent percentage of plasma protein binding is unavailable (22, 23) . As stated above, in this study, we observed little effect of serum and albumin on colistin activity.
The Enterobacteriaceae tested in this time-kill study showed at least a 3-log 10 reduction in the number of CFU/ml at 6 h on exposure to ceftazidime-avibactam at 4ϫ and 8ϫ MIC. Regrowth was observed at 24 h for most isolates. Ceftazidime-avibactam also produced a decrease in the number of CFU/ml at 6 h for the P. aeruginosa isolates tested; however, this combination was not bactericidal against these isolates, as defined by a 3-log 10 reduction in the number of CFU/ml for time-kill studies. The lack of bactericidal activity measured at 24 h for the Enterobacteriaceae was driven by regrowth, while for most P. aeruginosa isolates, it reflected lower degrees of initial killing coupled with regrowth, as evidenced by the fact that only 1 P. aeruginosa isolate had a 3-log 10 kill with 4ϫ MIC ceftazidime-avibactam at 6 h, whereas all 8 Enterobacteriaceae isolates had a 3-log 10 kill with 4ϫ MIC ceftazidime-avibactam at 6 h. We are uncertain about the clinical significance of this regrowth at 24 h, because the ceftazidime-avibactam clinical dosing regimen is every 8 h; however, it has been observed by others in in vitro time-kill assays using piperacillin-tazobactam (24) (25) (26) , colistin against Enterobacteriaceae (27) (28) (29) and P. aeruginosa (30) , and meropenem against bla KPC -positive K. pneumoniae (31) . In the piperacillin-tazobactam studies, regrowth at 24 h was observed when what the authors refer to as a high starting inoculum density of 5 ϫ 10 6 to 1 ϫ 10 7 CFU/ml was used but not when a lower inoculum density of 5 ϫ 10 5 CFU/ml was used (24, 25) . The authors suggested that there was an inoculum effect on the time-kill assay when using ␤-lactamase-producing strains (24, 25) . The starting inoculum in these studies was 1 ϫ 10 6 to 5 ϫ 10 6 CFU/ml, so it is possible that a higher inoculum may contribute to the observed regrowth. Additional studies would need to be performed in order to assess the impact of inoculum size on the shape of the time-kill curves.
The regrowth pattern observed with ceftazidime-avibactam in time-kill studies was further investigated by comparing the ceftazidime-avibactam time-kill curves to those of piperacillin-tazobactam and ceftazidime-tazobactam. For all isolates tested, there was regrowth at 24 h for all antibiotic-␤-lactamase inhibitor combinations tested. We found that adding additional avibactam at 6 h into the ceftazidime-avibactam time-kill study caused a decrease in regrowth otherwise observed at 24 h, but this effect was dependent on the isolate tested. A similar effect was seen when tazobactam was added to ceftazidime-tazobactam or piperacillin-tazobactam cultures at 6 h, but this occurred with only 1 of 4 isolates tested. These data indicate that the regrowth observed with these isolates is not unique to the ceftazidime-avibactam combination and does occur with other ␤-lactamase inhibitor combinations.
Avibactam dose-response time-kill curves showed that there was no significant effect of an increase in avibactam concentrations to greater than 4 g/ml, which is the standard concentration for the testing of avibactam in combination with ceftazidime (11). However, for one bla KPC-2 -, bla SHV-27 -, and bla TEM-1 -positive K. pneumoniae isolate (CML128) tested, concentrations of avibactam that were Ն8 g/ml prevented regrowth at 24 h, whereas Յ6 g/ml avibactam did not. It is not clear why increased avibactam concentrations affected this isolate differently from the other isolates tested, but it may be due to different ␤-lactamase expression levels between the isolates.
In comparison to the piperacillin-tazobactam and ceftazidime-tazobactam MICs, the ceftazidime-avibactam MICs for the isolates tested were lower, as listed in Table 3 . Therefore, the concentrations used in the ceftazidime-avibactam time-kill studies were lower than those used in the ceftazidime-tazobactam and piperacillin-tazobactam studies. We evaluated the activity of ceftazidime alone and ceftazidime-tazobactam at the same concentrations used in the ceftazidime-avibactam time-kill studies. Ceftazidime alone and ceftazidime-tazobactam displayed little antimicrobial activity against the isolates when tested at the same concentrations as ceftazidime-avibactam.
Evaluating ␤-lactam-␤-lactamase inhibitor combinations, such as ceftazidime-avibactam, in in vitro time-kill studies is challenging due to the fact that although ceftazidime is tested at multiples of the ceftazidime-avibactam MIC, avibactam is always tested at a fixed concentration of 4 g/ml. Under such circumstances the threshold concentration of avibactam may not be sufficient to protect the activity of ceftazidime over the 24-h period of a The concentration of ceftazidime was based on the ceftazidime-avibactam MIC. Inhibitors were tested at 4 g/ml. CML2255 was tested with ceftazidime-inhibitor at 0.5/4 g/ml, 1/4 g/ml, and 2/4 g/ml. CML128 was tested with ceftazidime-inhibitor at 2/4 g/ml, 4/4 g/ml, and 8/4 g/ml. CML1039 was tested was with ceftazidime-inhibitor at 16/4 g/ ml, 32/4 g/ml, and 64/4 g/ml. CML1040 was tested with ceftazidime-inhibitor at 2/4 g/ml, 4/4 g/ml, and 8/4 g/ml.
the study, and this may contribute to any regrowth. As mentioned above, similar observations of regrowth in time-kill studies have been made with other commercially available ␤-lactam-␤-lactamase inhibitor combinations, such as piperacillin-tazobactam (24) (25) (26) . Despite this phenomenon, piperacillin-tazobactam has been a cornerstone of antibacterial chemotherapy for many years, suggesting that regrowth in time-kill studies for ␤-lactam-␤-lactamase inhibitors might be an in vitro phenomenon that does not necessarily translate to an effect on clinical efficacy. The present study did show that ceftazidime-avibactam was bactericidal at 6 h against a diverse collection of ␤-lactamase-producing organisms. Ceftazidime-avibactam is being studied clinically at 2,000 mg/500 mg using a regimen of treatment once every 8 h with a 2-h infusion in phase 3 studies (ClinicalTrials.gov no. NCT01599806, NCT01499290, and NCT01808092). This treatment provides exposures that would exceed those studied in these in vitro time-kill assays. As stated above, this clinical dosing regimen provides ceftazidime-avibactam every 8 h, and thus, the regrowth seen at 24 h in vitro would likely not be applicable in a clinical setting. Furthermore, in animal experiments, the regrowth was not greater than the initial inoculum levels when simulated human exposures of ceftazidime-avibactam were established in neutropenic mice infected in the thigh or lung with P. aeruginosa (except for one isolate that did not regrow in thigh experiments in immunocompetent animals) (32, 33) . The average combined pharmacokinetics from this regimen have been shown to maintain adequate killing activity over the in vivo dosing interval against contemporary ␤-lactamase-producing organisms using simulated human dosing (32, 33) . Regardless of the limitations of testing in static in vitro assays, the bactericidal activity of ceftazidime-avibactam observed against highly ceftazidime-resistant isolates supports the ongoing clinical development of this combination.
